

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person * <b>FMR LLC</b>  (Last) (First) (Middle) <b>245 SUMMER STREET</b>  (Street) <b>BOSTON MA 02210</b>  (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <b>Structure Therapeutics Inc. [ GPCR ]</b>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) <input checked="" type="checkbox"/> Other (specify below)  <b>See Remark 1</b>
	3. Date of Earliest Transaction (Month/Day/Year) <b>12/08/2025</b>	
4. If Amendment, Date of Original Filed (Month/Day/Year)		

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)			4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price				
Ordinary Shares									36,909	I	F-Prime Capital Partners Life Sciences Advisors Fund VI LP
Ordinary Shares									434,298	I	F-Prime Capital Partners Life Sciences Advisors Fund VI LP

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	V	(A)	(D)	Date Exercisable	Expiration Date						Title
American Depository Shares	(1)							(1)	(1)	Ordinary Shares	4,546,674	1,515,558	I	Shares held by persons and entities whose shares are subject to reporting by the undersigned	
American Depository Shares	(1)	12/08/2025		S			709	(1)	(1)	Ordinary Shares	2,127	\$92.52 <sup>(2)</sup>	3,393	I	F-Prime Capital Partners Life Sciences Advisors Fund VI LP
American Depository Shares	(1)	12/08/2025		S			183	(1)	(1)	Ordinary Shares	549	\$94 <sup>(3)</sup>	3,210	I	F-Prime Capital Partners Life Sciences Advisors Fund VI LP

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned  
(e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)				6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
American Depositary Shares	(I)	12/08/2025		S			475	(I)	(I)	Ordinary Shares	1,425	\$94.61 <sup>(4)</sup>	2,735	I	F-Prime Capital Partners Life Sciences Advisors Fund VI LP
American Depositary Shares	(I)	12/08/2025		S			1,414	(I)	(I)	Ordinary Shares	4,242	\$61.05 <sup>(5)</sup>	1,321	I	F-Prime Capital Partners Life Sciences Advisors Fund VI LP
American Depositary Shares	(I)	12/08/2025		S			1,320	(I)	(I)	Ordinary Shares	3,960	\$61.45 <sup>(6)</sup>	1	I	F-Prime Capital Partners Life Sciences Advisors Fund VI LP
American Depositary Shares	(I)	12/08/2025		S			8,337	(I)	(I)	Ordinary Shares	25,011	\$92.52 <sup>(2)</sup>	39,918	I	F-Prime Capital Partners Life Sciences Fund VI LP
American Depositary Shares	(I)	12/08/2025		S			2,159	(I)	(I)	Ordinary Shares	6,477	\$94 <sup>(3)</sup>	37,759	I	F-Prime Capital Partners Life Sciences Fund VI LP
American Depositary Shares	(I)	12/08/2025		S			5,589	(I)	(I)	Ordinary Shares	16,767	\$94.61 <sup>(4)</sup>	32,170	I	F-Prime Capital Partners Life Sciences Fund VI LP
American Depositary Shares	(I)	12/08/2025		S			16,635	(I)	(I)	Ordinary Shares	49,905	\$61.05 <sup>(5)</sup>	15,535	I	F-Prime Capital Partners Life Sciences Fund VI LP
American Depositary Shares	(I)	12/08/2025		S			15,535	(I)	(I)	Ordinary Shares	46,605	\$61.45 <sup>(6)</sup>	0	I	F-Prime Capital Partners Life Sciences Fund VI LP

**Explanation of Responses:**

- Reported securities are American Depositary Shares, each of which represents three Ordinary Shares of the Issuer. Any one American Depositary Share may be converted into three Ordinary Shares, and any three Ordinary Shares into one American Depositary Share, at any time at the election of the holder upon notice.
- The price reported for this transaction is the weighted average price of multiple trades at prices ranging from \$92.29 to \$92.93. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information.
- The price reported for this transaction is the weighted average price of multiple trades at prices ranging from \$93.27 to \$94.26. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information.
- The price reported for this transaction is the weighted average price of multiple trades at prices ranging from \$94.28 to \$94.88. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information.
- The price reported for this transaction is the weighted average price of multiple trades at prices ranging from \$60.32 to \$61.31. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information.
- The price reported for this transaction is the weighted average price of multiple trades at prices ranging from \$61.32 to \$61.64. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information.

**Remarks:**

Remark 1: Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders' voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders' voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. The address of Abigail P. Johnson is c/o FMR LLC, 245 Summer Street, Boston, MA 02110. Remark 2: The filing of this statement shall not be deemed to be an admission that, for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise, the undersigned are the beneficial owners of any securities reported herein. Remark 3: F-Prime Capital Partners Life Sciences Advisors Fund VI LP (FPCPLSA) is the general partner of F-Prime Capital Partners Life Sciences Fund VI LP. FPCPLSA is solely managed by Impresa Management LLC, the managing member of its general partner and its investment manager. Impresa Management LLC is owned, directly or indirectly, by various shareholders and employees of FMR LLC, including certain members of the Johnson family.

/s/ Stephanie J. Brown, Duly  
authorized under Powers of  
Attorney, by and on behalf of  
FMR LLC and its direct and  
indirect subsidiaries, and Abigail  
P. Johnson 12/10/2025

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**